Karyopharm Therapeutics | KPTI - Operating Expenses

Stock Price
8.55
Daily Change
0.10 1.18%
Monthly
0%
Yearly
93.44%
Q2 Forecast
7.78

Karyopharm Therapeutics reported $51.92M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Abbott USD 9.21B 17M Dec/2025
Amgen USD 5.9B 773M Dec/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
BioCryst Pharmaceuticals USD 146.17M 534.06M Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
Incyte USD 1.12B 3.53B Dec/2025
J&J USD 17.44B 1.53B Mar/2026
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
MacroGenics USD 53.32M 13.68M Dec/2025
Merck USD 10.16B 558M Dec/2025
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Novartis USD 9.8B 61M Dec/2025
Novartis USD 9.8B 23M Dec/2025
Pfizer USD 12.91B 79.89B Dec/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Takeda JPY 1.02T 400.98B Dec/2025
Tectonic Therapeutic USD 21.52M 374K Dec/2025
TG Therapeutics USD 142.08M 9.74M Dec/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
Xencor USD 81.86M 13.35M Dec/2025